Leo Laboratories Limited

Aclaris Therapeutics, Inc.

Palvella Therapeutics, Inc.

Helperby Therapeutics Limited

Pellepharm, Inc.

Timber Pharmaceuticals LLC

Jagotec Ag

Endomagnetics Limited

Leo Laboratories Limted

Medpharm Limited

Sol-Gel Technologies Ltd.

Stuart Allen Jones

Marc Barry Brown

Patagonia Pharmaceuticals, LLC

Charles Rodney Greenaway Evans

Tahir Nazir

Braham Shroot

Michael A Botta

Stuart D Shanler

Christopher Phillips

Christopher Powala

Thomas Nagler

Sian Tiong Lim

Simon David Betson

Wesley Harton Kaupinen

Brian Beger

Michael Edward Donald Crothers

Michael Crothers

Michael Edward Donald Crowthers

Hazel Joan Dyke

Thomas David Pallin

David Edward Clark

Yanmin Hu

Derek John Londesbrough

Anthony Coates

Gary Patrick Reid

Cameron Robert Stevenson

Keith Mills

Petra Helga Beck

Gerlinda Stoddart

Zachary Rome

Francesco Caserta

Christopher Marriott

Andrew P Shawcross

John Gonzalez-Carvajal

Rob Turner

Gary Peter Martin

Charles Rodney Evans

Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Anhydrous compositions of mTOR inhibitors and methods of use

Provided herein are novel isotretinoin formulations that provide an enhanced targeted dermal delivery system for the drug isotretinoin with improved thermodynamic activity using no to a small level of ethanol relative to existing isotretinoin gel products, and methods for treatment of ichthyosis and other skin conditions using the same.

Isotretinoin formulations and uses and methods thereof

Compositions for topical administration of a hedgehog inhibitor compound are described. In one embodiment, the hedgehog inhibitor compound is patidegib and the topical composition comprises the compound in a solvent system of a monohydric primary alcohol and a polyol in a w/w ratio of between about 0.9-1.8. In another embodiment, the hedgehog inhibitor is itraconazole and the topical composition comprises the compound in a solvent system comprising a monohydric primary alcohol and an optionally lower alkyl end-capped oligomeric alkylene glycol in a w/w ratio of between about 0.8 and 2.6 and a fused bicyclic ether. Method of using the compositions are also described, where in one embodiment, the compositions are topically applied for treating or preventing basal cell carcinoma.

Topical formulations for delivery of hedgehog inhibitor compounds and use thereof

Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts,accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

Peroxide formulations and methods and applicators for using the same

Anyhydrous compositions of mTOR inhibitors and methods of use

Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

There is provided the use of compounds of formula I wherein R, R, Rand X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.

Use of pyrroloquinoline compounds to kill clinically latent microorganisms

Growing community of inventors

Watford, United Kingdom

Marc Barry Brown